Evaluation of Crohn’s Disease Small-Bowel Mucosal Healing Using Capsule Endoscopy and Usefulness of Leucine-Rich α2-Glycoprotein

Autor: Hiroto Hiraga, Daisuke Chinda, Keisuke Hasui, Yasuhisa Murai, Takato Maeda, Naoki Higuchi, Kohei Ogasawara, Sae Kudo, Yohei Sawada, Tetsuya Tatsuta, Hidezumi Kikuchi, Mami Ebina, Noriko Hiraga, Tatsuya Mikami, Hirotake Sakuraba, Shinsaku Fukuda
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Diagnostics, Vol 13, Iss 4, p 626 (2023)
Druh dokumentu: article
ISSN: 13040626
2075-4418
DOI: 10.3390/diagnostics13040626
Popis: Recently, the importance of achieving clinical and deep remissions with mucosal healing (MH) has been demonstrated as a therapeutic goal to avoid Crohn’s disease (CD) surgical operations. Although ileocolonoscopy (CS) is considered the gold standard, there are increasing reports on the benefits of capsule endoscopy (CE) and serum leucine-rich α2-glycoprotein (LRG) for evaluating small-bowel lesions in CD. We evaluated the data of 20 patients with CD who underwent CE in our department between July 2020 and June 2021 and whose serum LRG level was measured within 2 months. Concerning the mean LRG value, there was no significant difference between the CS-MH and CS-non-MH groups. Conversely, the mean LRG level was 10.0 μg/mL in seven patients in the CE-MH group and 15.2 μg/mL in 11 patients in the CE-non-MH group with a significant difference between the two groups (p = 0.0025). This study’s findings show that CE can sufficiently determine total MH in most cases, and LRG is useful for evaluating CD small-bowel MH because of its correlation with CE-MH. Furthermore, satisfying CS-MH criteria and a cut-off value of 13.4 μg/mL for LRG suggests its usefulness as a CD small-bowel MH marker, which could be incorporated into the treat-to-target strategy.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje